A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer-Reference-Cited by-同舟云学术

A Y1 receptor ligand synergized with a P-glycoprotein inhibitor improves the therapeutic efficacy of multidrug resistant breast cancer

Published:2019 Issue:11 Volume:7 Page:4748-4757
ISSN:2047-4830
Container-title:Biomaterials Science
language:en
Short-container-title:Biomater. Sci.

Author:

Wang Yinjie¹²³⁴⁵,Jiang Zhenqi¹²³⁴⁵,Yuan Bo¹²³⁴⁵,Tian Yuchen¹²³⁴⁵,Xiang Lingchao¹²³⁴⁵,Li Yanying¹²³⁴⁵,Yang Yong⁶⁷⁸⁹¹⁰,Li Juan¹²³⁴⁵^ORCID,Wu Aiguo¹²³⁴⁵^ORCID

Affiliation:

1. Cixi Institute of Biomedical Engineering

2. CAS Key Laboratory of Magnetic Materials and Devices

3. & Key Laboratory of Additive Manufacturing Materials of Zhejiang Province

4. Ningbo Institute of Materials Technology and Engineering

5. Chinese Academy of Sciences

6. Department of Clinical Laboratory

7. the Affiliated Hospital of Medical School of Ningbo University

8. Ningbo University School of Medicine

9. Ningbo

10. China

Abstract

A Y₁ receptor ligand stabilizes doxorubicin and P-gp inhibitor tariquidar co-loaded nanomicelles during systemic circulation, generating excellent tumor targeting and antitumor efficacy with prolonged survival and minimized liver metastasis.

Funder

National Natural Science Foundation of China

Youth Innovation Promotion Association

Ningbo Municipal Bureau of Science and Technology

Ministry of Science and Technology of the People's Republic of China

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Biomedical Engineering

Link

http://pubs.rsc.org/en/content/articlepdf/2019/BM/C9BM00337A

Reference41 articles.